ClinicalTrials.gg
TerminatedNCT02242812Updated Sep 17, 2014

Telmisartan Effectiveness on Left Ventricular Mass Reduction (TELMAR) as Assessed by MRI, in Patients With Mild to Moderate Hypertension

A Phase 4 interventional study of Telmisartan and Metoprolol succinate in Hypertension, sponsored by Boehringer Ingelheim. Terminated. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-09-17.

Sponsored by Boehringer Ingelheim · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 99 studies testing telmisartan in Hypertension — 1 open to participants now, 1 under way, none of them phase 3. Telmisartan · Hypertension.

Enrollment
92nd of 99
24 · median 184
Started
2003
with 4 others
Phase 4
32 of 99
1 open now
Registered
69th of 99
by date
Lead sponsor
48 of 99
Boehringer Ingelheim

Among the 99 studies testing telmisartan in Hypertension, this one is the 92nd largest by enrollment, is one of 5 that started in 2003, is one of 32 in phase 4, and was the 69th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 99 studies testing telmisartan in Hypertension is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About telmisartan

Telmisartan: first FDA approval 1998 (MICARDIS), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 99 studies testing telmisartan in Hypertension, or all of them as a file.
02

Study summary

The primary objective was to show that telmisartan is not inferior to metoprolol succinate in respect of the percentage change from baseline in LVMI(H) after a 6.5 months treatment period. As secondary objectives, the improvement in left ventricular systolic and diastolic function and blood pressure reduction were assessed

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian and non-Caucasian patients i.e. Asian patients with untreated essential hypertension as defined by either a mean systolic blood pressure (SBP) of >= 140 mm Hg or a mean diastolic blood pressure (DBP) of >= 90 mm Hg during normal daily activities (6:00 - 21:59 h) and/or a nocturnal (22:00 - 05:59 h) SBP mean of >= 120 mm Hg or a DBP mean of >= 70 mm Hg as measured by ABPM.
  • Presence of Left Ventricular Hypertrophy (LVH) as defined by MRI:

    • Caucasian patients: Left ventricular mass of > 0.8 g/cm for women or > 1.05 g/cm for men. Non-Caucasian i.e. Asian patients: Left ventricular mass of > 0.65 g/cm for women or > 0.85 g/cm for men
  • Age between 18 and 80 years
  • Written in accordance with Good Clinical Practice (GCP) guidelines and the local regulatory and legal requirements

Exclusion criteria

Exclusion Criteria:

  • to the class of drugs under study:

    • Contraindications against β Blocker or angiotensin receptor antagonists
    • A history of angioedema or known to any component of the formulations
  • Contraindications on ethical grounds:

    • there are no specific contraindications ethical grounds foreseen in this study
  • General Contraindications:

    • Pregnancy, lactation or child bearing potential (I.e. Pre-menopausal women (last menstruation \< 1 year prior to start of run-in phase) who are not surgically sterile (hysterectomy, tubal ligation) or who are NOR practicing or do NOT plan to practice acceptable means of (Intrauterine Device, oral implantable or injectable contraceptives) or who have a positive serum pregnancy test at screening or baseline)
    • Factors making follow up difficult (i.e. no fixed address)
    • Treatment with other drugs within one month of signing
  • concomitant diseases:

    • Hepatic and/or renal dysfunction as defined by the following laboratory parameters:

      1. Alanine amino transferase ( (ALT)) or Aspartate amino transferase (SGOT (AST)) values above two times or Gamma glutaryl transferase (Gamma-GT) three times the upper normal limit
      2. Serum creatinine > 150 mol/L
    • Clinically significant sodium or potassium depletion, clinically relevant hyperkalaemia
    • Uncorrected volume depletion
    • Primary aldosteronism
    • Hereditary fructose intolerance
    • Biliary obstructive disorders, cholestasis or moderate to severe hepatic insufficiency
    • Insulin-dependent diabetes mellitus
    • Congestive heart failure or \< 35% (NYHA) class III or IV
    • Unstable Angina
    • Sustained ventricular tachycardia, atrial fibrillation, atrial flutter or other clinically relevant cardiac arrhythmias as determined by the investigator
    • Post-renal transplant patients
    • Myocardial infarction or cardiac surgery within the preceding six months
  • Known drug or alcohol abuse within 6 months prior to start of study
  • Patients with MRI contraindications:

    • Implanted pacemaker or defibrillator
    • Implanted vascular clips
    • Gross obesity (i.e. patients weight > 150 kg)
  • Specific exclusion for the disease under study:

    • Known or suspected secondary hypertension
    • Known renal artery stenosis
    • Known endocrine disorders with secondary hypertension
    • Severe arterial hypertension as defined by a mean seated DBP > 115 mmHg or a mean seated SBP > 200 mmHg
    • Patients with a complete loss of diurnal BP variation, as defined by the lack of drop of BP during sleeping time or a drop of less than 5% when compared to daily mean BP
    • Hypertrophic obstructive cardiomyopathy, clinically relevant aortic valve stenosis or clinically relevant mitral valve disease; vascular disease affecting BP (coarctation; stenosis of A. subclavia)
  • Specific concomitant therapy exclusions:

    • Use of antihypertensive medication within the previous six months
    • Chronic administration of digoxin or other digitalis-type drugs, without regular monitoring of plasma level
    • Chronic administration of any medications known to affect blood pressure, except medications allowed by the protocol
    • Continuous (for more than two weeks) treatment within the last three months using at least on of the following drugs: β blockers, angiotensin converting enzyme inhibitors, angiotensin receptor blockers
  • Participation in another drug trial
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Telmisartan

    MICARDIS®

    Drug: Telmisartan · Drug: Placebo

  • Active comparator
    Metoprolol succinate

    BELOC ZOK®

    Drug: Metoprolol succinate · Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage change in left ventricular mass index relative to height (LVMI(H))

    based on LVM measurements by magnetic resonance imaging (MRI)

    Time frame: Baseline, day 180

Secondary outcomes

  1. Number of patients with adverse events

    Time frame: up to 6.5 months

  2. Change of left ventricular mass index related to the body surface area (LVMI (BSA)) measured by MRI

    Time frame: Baseline, day 180

  3. Change of left ventricular end-systolic (LVESV) measured by MRI

    Time frame: Baseline, day 180

  4. Change of left ventricular end-diastolic volume (LVEDV) as measured by MRI

    Time frame: Baseline, day 180

  5. Change of left ventricular end-diastolic volume index related to height LVEDVI (H))

    based on LV volumetric measurements by MRI

    Time frame: Baseline, day 180

  6. Change of left ventricular end-diastolic volume index related to the body mass index (LVEDVI (BSA))

    based on LV volumetric measurements by MRI

    Time frame: Baseline, day 180

  7. Change of left ventricular ejection fraction (EF)

    based on LV volumetric measurements by MRI

    Time frame: Baseline, day 180

  8. Change of end-systolic wall stress (ESWS) measured by MRI

    Time frame: Baseline, day 180

  9. Change of 24-hour mean systolic blood pressure measured by ambulatory blood pressure monitoring (ABPM)

    Time frame: Baseline, day 179

  10. Change of 24-hour mean diastolic blood pressure as measure by ABPM

    Time frame: Baseline, day 179

  11. Change of mean seated trough systolic blood pressure measured by manual cuff sphygmomanometer

    Time frame: up to day 194

  12. Change of mean seated trough diastolic blood pressure measured by manual cuff sphygmomanometer

    Time frame: up to day 194

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2003 and a primary completion of Oct 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2014
First posted
Sep 17, 2014
Start
Sep 2003
Primary completionActual
Oct 2004
Last update
Sep 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02242812
Responsible party
Sponsor
First posted
Sep 17, 2014
Start date
Sep 2003
Primary completion
Oct 2004
Last update
Sep 17, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion